Given this evidence, we hypothesized that the circadian gene Bmal1 might participate in the pathogenesis of diabetic cardiomyopathy and that such a connection would furnish new opportunities for mechanism-based diabetic cardiomyopathy therapeutics. The gene discussed is BMAL1; the disease is diabetic cardiomyopathy.